{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:24Z","timestamp":1740107424759,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00280-015-2912-7","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T02:56:27Z","timestamp":1452480987000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects"],"prefix":"10.1007","volume":"77","author":[{"given":"Sabiha A.","family":"Mondal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"O\u2019Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM (2010) Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia 24:22\u201332. doi: 10.1038\/leu.2009.236","journal-title":"Leukemia"},{"key":"2912_CR2","volume-title":"Summary of product characteristics","author":"Imnovid (pomalidomide)","year":"2015","unstructured":"Imnovid (pomalidomide) (2015) Summary of product characteristics. Celgene Europe Ltd., Uxbridge"},{"key":"2912_CR3","volume-title":"Package insert","author":"Pomalyst (pomalidomide)","year":"2015","unstructured":"Pomalyst (pomalidomide) (2015) Package insert. Celgene Corporation, Summit"},{"key":"2912_CR4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R et al (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123:1826\u20131832. doi: 10.1182\/blood-2013-11-538835","journal-title":"Blood"},{"key":"2912_CR5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055\u20131066. doi: 10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"key":"2912_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","volume":"71","author":"M Hoffmann","year":"2013","unstructured":"Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G (2013) Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 71:489\u2013501. doi: 10.1007\/s00280-012-2040-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"2912_CR7","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22:3269\u20133276. doi: 10.1200\/JCO.2004.10.052","journal-title":"J Clin Oncol"},{"key":"2912_CR8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.384","volume":"55","author":"C Kasserra","year":"2015","unstructured":"Kasserra C, Assaf M, Hoffmann M, Li Y, Liu L, Wang X, Kumar G, Palmisano M (2015) Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug\u2013drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol 55:168\u2013178. doi: 10.1002\/jcph.384","journal-title":"J Clin Pharmacol"},{"key":"2912_CR9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/FJC.0b013e318217d941","volume":"57","author":"P Vigneault","year":"2011","unstructured":"Vigneault P, Kaddar N, Bourgault S, Caillier B, Pilote S, Patoine D, Simard C, Drolet B (2011) Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? J Cardiovasc Pharmacol 57:690\u2013695. doi: 10.1097\/FJC.0b013e318217d941","journal-title":"J Cardiovasc Pharmacol"},{"key":"2912_CR10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjp.0706892","volume":"149","author":"S Rajamani","year":"2006","unstructured":"Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481\u2013489. doi: 10.1038\/sj.bjp.0706892","journal-title":"Br J Pharmacol"},{"key":"2912_CR11","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) ICH harmonised tripartite guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf . Accessed 2 Sept 2015"},{"key":"2912_CR12","unstructured":"US Food and Drug Administration: Center for Drug Evaluation and Research. POMALYST (pomalidomide) NDA 204026. Pharmacology\/toxicology NDA review and evaluation. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204026Orig1s000PharmR.pdf . Accessed 2 Sept 2015"},{"key":"2912_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12081","volume":"113","author":"N Chen","year":"2013","unstructured":"Chen N, Ye Y, Liu L, Reyes J, Assaf MS, Kasserra C, Zhou S, Palmisano M (2013) Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol 113:179\u2013186. doi: 10.1111\/bcpt.12081","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2912_CR14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2008.33","volume":"84","author":"DM Bloomfield","year":"2008","unstructured":"Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA (2008) The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84:475\u2013480","journal-title":"Clin Pharmacol Ther"},{"key":"2912_CR15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia LS (1920) Die systolendauer im elektrokardiogramm bei normalen menschen und bei Herzkranken. Acta Med Scand 53:469\u2013486","journal-title":"Acta Med Scand"},{"key":"2912_CR16","unstructured":"Food and Drug Administration (2005) Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073153.pdf . Accessed 4 Sept 2015"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2912-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2912-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:39Z","timestamp":1559023659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2912-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2912-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}